Healio
Healio
More about

Dmard

Clinical Guidance
Psoriasis
Treatment Options

Oral Systemic Therapy for Psoriasis

Eric M. Ruderman, MD; Kenneth B. Gordon, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Rheumatoid Arthritis
Treatment Options

Conventional Synthetic Disease-Modifying Antirheumatic Drugs

John J. Cush, MD; Michael E. Weinblatt, MD; Arthur Kavanaugh, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Rheumatoid Arthritis
Treatment Options

Corticosteroid Therapy

John J. Cush, MD; Michael E. Weinblatt, MD; Arthur Kavanaugh, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Rheumatoid Arthritis
Treatment Guidelines

Pharmacotherapy and Management Guidelines

John J. Cush, MD; Michael E. Weinblatt, MD; Arthur Kavanaugh, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Rheumatoid Arthritis
Presentation and Diagnosis

Diagnosis of Early Rheumatoid Arthritis

John J. Cush, MD; Michael E. Weinblatt, MD; Arthur Kavanaugh, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Ankylosing Spondylitis
Assessment and Treatment

Assessment and Monitoring

Muhammad Asim Kahn, MD, FRCP, MACP; Nurullah Akkoç, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Ankylosing Spondylitis
Presentation and Diagnosis

Impact of COVID-19 Pandemic on the Care of Patients With axSpA

Muhammad Asim Kahn, MD, FRCP, MACP; Nurullah Akkoç, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

News
June 27, 2024
2 min read
Save

Upadacitinib’s risk-benefit profile in rheumatoid arthritis ‘favorable’ through 5 years

Upadacitinib’s risk-benefit profile in rheumatoid arthritis ‘favorable’ through 5 years

The risk-benefit profile of upadacitinib for rheumatoid arthritis “remains favorable” through 5 years, according to data published in The Journal of Rheumatology.

News
June 26, 2024
2 min read
Save

Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes

Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes

Bimekizumab treatment for psoriatic arthritis demonstrated rapid, clinically meaningful improvements to patient reported outcomes that were sustained up to 1 year, according to data published in Rheumatology.

News
April 09, 2024
2 min read
Save

Nearly 40% of children with oligoarthritis need no other therapy after steroid injection

Nearly 40% of children with oligoarthritis need no other therapy after steroid injection

Nearly 40% of children with oligoarticular juvenile idiopathic arthritis treated with intra-articular corticosteroids required no additional therapy, according to data published in Arthritis Research & Therapy.

View more